awards grant A MULTICENTER, OPEN-LABEL, PHASE 1B STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SULBACTAM-DURLOBACTAM IN HOSPITALIZED PEDIATRIC PATIENTS FROM BIRTH TO <18 YEARS WHO ARE RECEIVING SYSTEMIC ANTIBIOTIC THERAPY FOR SUSPECTED OR CONFIRMED ACINETOBACTER BAUMANNII-CALCOACETICUS COMPLEX INFECTION
